CHAPEL HILL, N.C., June 13 /PRNewswire/ -- Best Practices, LLC's latest benchmarking study explains how U.S. pharmaceutical and biotechnology organizations can optimize their CI operations while working within defined guidelines.
Particular attention is paid to CI information sources, what is being collected, and how CI groups work within legal groups to develop standard operating procedures for data collection that are in the best interests of the organization as a whole and to maximize the CI department's ability to deliver results.
Savvy CI leaders employ multiple, even overlapping, secondary data sources and triangulate from them to develop the most accurate information and projections, described in the newly published study, "Pharmaceutical Competitive Intelligence Excellence: Optimizing Data Collection with Approved Guidelines" by Best Practices, LLC. Click here for complimentary download: http://www3.best-in-class.com/dr316.htm
Executives from many of the top 50 pharmaceutical companies have found that one of the most useful tools that they have at their disposal when it comes to gaining information and benchmarking best practices about competitive intelligence is the Best Practices Database. To view a list of just some of the documents pertaining to competitive intelligence click on this link: http://www3.best-in-class.com/dr316.htm
Best Practices Database covers many key functionality areas pertaining
to Pharma Industry such as:
-- Resources and strategies required to gain crucial market access
-- Creating blockbusters in an increasingly competitive marketplace
-- Publications strategies that give credibility and increase reputation
-- Key to building effective brand teams
-- Case studies for successful re-launches
-- Strategies for successful
|SOURCE Best Practices, LLC|
Copyright©2008 PR Newswire.
All rights reserved